Commercial insurance delays direct‐acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients

Abstract

D+/R- transplantation offers patients an alternative strategy to increase access. However, treatment can be profoundly delayed by a third-party payer authorization process that may be subjecting patients to unnecessary risks and worsened outcomes.